bioRxiv
Flu vaccine additive linked to faster antibody rises in adults
A randomized trial analysis followed 56 younger and older adults for 180 days and found no significant difference in overall antibody levels between vaccine groups.A randomized trial analysis followed 56 younger and older adults for 180 days and found no significant difference in overall antibody levels between vaccine groups.
Preprint: randomized trial · 56 peopleInterventions
Who was studied56 younger and older adults, 180 days, against QIIV alone
What changedEarly IgG3 antibody rise was higher with adjuvant: log2-fold change 7.10±4.30 against 4.84±3.56 with vaccine alone
The catchOnly 28 participants per group were analyzed